Insights from 2023 ASCO® Annual Meeting
Playback speed
10 seconds
ASCO® 2023 Insights: "A Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Acalabrutinib vs. Zanubrutinib in R/R CLL"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Adam Kittai
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Adam Kittai
558 views
June 9, 2023
Comments 0
Login to view comments.
Click here to Login
Hematology